União Europeia - sueco - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatiska neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

actavis group ptc ehf. - fludarabinfosfat - koncentrat till injektions-/infusionsvätska, lösning - 25 mg/ml - fludarabinfosfat 25 mg aktiv substans - fludarabin

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

teva sweden ab - tenofovirdisoproxilfosfat - filmdragerad tablett - 245 mg - tenofovirdisoproxilfosfat 291,22 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne - tenofovirdisoproxil

União Europeia - sueco - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - bröst-neoplasmer - endokrin terapi, anti-östrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausala kvinnor, kombinationsbehandling med palbociclib bör kombineras med en luteinizing hormone releasing hormone (gnrh) agonist.

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

teva sweden ab - deferasirox - dispergerbar tablett - 250 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; deferasirox 250 mg aktiv substans

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

teva sweden ab - deferasirox - dispergerbar tablett - 125 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; deferasirox 125 mg aktiv substans

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

teva sweden ab - deferasirox - dispergerbar tablett - 500 mg - deferasirox 500 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

hormosan pharma gmbh - naloxonhydrokloriddihydrat; oxikodonhydroklorid - depottablett - 40 mg/20 mg - oxikodonhydroklorid 40 mg aktiv substans; stearylalkohol hjälpämne; naloxonhydrokloriddihydrat 22 mg aktiv substans

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

hormosan pharma gmbh - naloxonhydrokloriddihydrat; oxikodonhydroklorid - depottablett - 10 mg/5 mg - oxikodonhydroklorid 10 mg aktiv substans; stearylalkohol hjälpämne; laktosmonohydrat hjälpämne; naloxonhydrokloriddihydrat 5,5 mg aktiv substans

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

hormosan pharma gmbh - naloxonhydrokloriddihydrat; oxikodonhydroklorid - depottablett - 20 mg/10 mg - naloxonhydrokloriddihydrat 11 mg aktiv substans; stearylalkohol hjälpämne; oxikodonhydroklorid 20 mg aktiv substans